|Videos|September 19, 2022
Dr. Shore on next steps with PARP inhibitors in prostate cancer
Author(s)Urology Times staff
Advertisement
Neal D. Shore, MD, discusses what’s on the horizon with PARP inhibitors in the treatment paradigm for patients with prostate cancer. Shore is medical director for the Carolina Urologic Research Center and chief medical officer, Surgical Oncology and Urology, for Genesis Care (US).
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Urology Times
1
Alternative BCG strains may help address ongoing supply challenges in NMIBC
2
Pearls & Perspectives: Sexual Health and Intimacy in Midlife, With Karen Bigman, MBA
3
Doublet or triplet? Urologists weighs in on mCSPC options
4
Phase 3 trial of padeliporfin VTP completes treatment in LG-UTUC
5